🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

8,395 results for “La” Clear

  1. "myk-461 capsules, placebo is a solid oral dosage form in size 2 gelatin capsules each containing 120 mg of an excipient blend. it is intended as a placebo to match myk-461 capsules of all active strengths", Mavacamten, Mavacamten, Mavacamten, Mavacamten, Mavacamten

    Bristol-Myers Squibb Australia Pty Ltd

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. ,4-diaminopyridine

    Ultragenyx UK Limited

    Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

    phase 3 small molecule completed

    1 trial

  3. -, -, ERYTHROPOIETIN , DANAZOL , VAY736, -, ENTECAVIR , Placebo to VAY736 150 mg/1 mL concentrate for solution for infusion, -, -

    Novartis Pharmaceuticals

    warm autoimmune haemolytic anaemia (wAIHA)

    phase 3 small molecule active

    1 trial

  4. -, -, IMETELSTAT, -, -, -, -, -, -, -

    Geron Netherlands B.V.

    Myelofibrosis

    phase 3 small molecule active

    1 trial

  5. -, Apalutamide placebo, JNJ-56021927

    Janssen-Cilag International N.V.

    Metastatic Hormone-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  6. -, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide

    Sanofi-aventis Healthcare Pty Ltd

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  7. -, PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., MK-2870, MVASI 25 mg/mL concentrate for solution for infusion, CARBOPLATIN , MVASI 25 mg/mL concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion., CISPLATIN

    Merck Sharp and Dohme

    Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1

    phase 3 small molecule active

    1 trial

  8. -, PARACETAMOL , CILAZAPRIL , Dapirolizumab pegol, EPINEPHRINE , DIPHENHYDRAMINE , -, -, -, -, -, -, -

    Lacuna Pharma Pty Ltd

    Systemic lupus erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  9. -, PARACETAMOL , MK-2870, PACLITAXEL , -, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -, CARBOPLATIN , PACLITAXEL ALBUMIN-BOUND, DEXAMETHASONE

    Merck Sharp and Dohme

    Participants with treatment-naïve metastatic squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  10. -, Placebo to ianalumab 150 mg/1 mL concentrate for solution for infusion, -, ENTECAVIR , -, ELTROMBOPAG, -, ELTROMBOPAG, ELTROMBOPAG, VAY736, -, ELTROMBOPAG

    Novartis Pharmaceuticals

    Primary immune thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  11. -, Rozanolixizumab

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  12. -, Rozanolixizumab

    Lacuna Pharma Pty Ltd

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  13. -, TACROLIMUS , Amlitelimab, PIMECROLIMUS , Placebo, Amlitelimab

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  14. -, TECHNETIUM (99MTC) COMPOUNDS, -, JNJ-56021927

    Janssen-Cilag International N.V.

    High risk recurrent prostate cancer previously treated with radical prostatectomy

    phase 3 small molecule active

    1 trial

  15. 0.9 % w/v Sodium Chloride Injection, Reblozyl 25 mg powder for solution for injection, Reblozyl 75 mg powder for solution for injection

    Celgene Europe Limited

    Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF)

    phase 3 small molecule active

    1 trial

  16. 0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran

    Alnylam Netherlands B.V.

    High cardiovascular risk, Established cardiovascular disease, Hypertension

    phase 3 small molecule active

    1 trial

  17. 0.9% Sodium Chloride for Injection, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., JEMPERLI 500 mg concentrate for solution for infusion

    GlaxoSmithKline

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  18. 0.9% Sodium chloride, Amvuttra 25 mg solution for injection in pre-filled syringe

    Alnylam Netherlands B.V.

    Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

    phase 3 small molecule active

    1 trial

  19. 0.9% sodium chloride, Lepodisiran

    Eli Lilly Co.

    Atherosclerotic Cardiovascular Disease Elevated lp(a)

    phase 3 small molecule active

    1 trial

  20. 1% Clascoterone Cream

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Acne Vulgaris

    phase 3 small molecule active

    1 trial

  21. 18F-AV-1451

    The George Institute

    Maladie d' Alzheimer, Alzheimer's pathology

    phase 3 small molecule active

    1 trial

  22. 2 mg Melatonin

    United Therapeutics Europe Ltd

    Anxiety

    phase 3 small molecule completed

    1 trial

  23. 2.0 mg intravitreal aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  24. 20 mg VEC-162

    Vanda Pharmaceuticals Netherlands B.V.

    Insomnia

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources